For a condition that affects roughly one in eight women of reproductive age in Australia, the support that follows a diagnosis is often remarkably thin. Most women leave that appointment with more questions than answers, and end up piecing together a treatment plan from specialist appointments, online forums, and sheer persistence. It doesn't have to be that way, and understanding the full pathway makes it considerably less overwhelming.

A new name for a long misunderstood condition

If you were diagnosed some time ago, you may know this condition as polycystic ovary syndrome (PCOS). In May 2026, following more than a decade of advocacy from researchers, clinicians, and people with lived experience, it was officially renamed polyendocrine metabolic ovarian syndrome, or PMOS, in a landmark announcement published in The Lancet.

The renaming matters. The old name put cysts at the centre of a condition that is fundamentally hormonal and metabolic. Many women with PMOS don't have visible cysts at all, and the previous name led to missed diagnoses, confusion, and a narrow focus on the ovaries when the condition affects the whole body. The new name better reflects what PMOS actually is, and places GPs in a stronger position to diagnose and manage it with confidence.

You may still see PCOS used in older resources during the transition period, which runs until the full International Guideline update in 2028. Both names refer to the same condition.

What PMOS actually does to ovulation

PMOS is a complex hormonal condition, not simply a structural one. The hormonal picture is what drives the diagnosis: elevated androgens, irregular or absent ovulation, and often, though not always, insulin resistance.

Insulin resistance is the piece that tends to get underdiscussed. When cells become resistant to insulin, the pancreas compensates by producing more of it. Higher insulin levels stimulate the ovaries to produce more androgens, which disrupts the normal hormone cycle that triggers ovulation. The result is follicles that develop but don't mature fully, cycles that are long and irregular, and fertility that is reduced but not absent.

This matters for treatment because addressing insulin resistance, through lifestyle changes, medication, or both, can restore ovulation in some women without any fertility-specific intervention.

The treatment pathway, and why it isn't always linear

Treatment for PMOS-related infertility follows a stepped approach, but the steps aren't always taken in strict order. What's right depends on your full picture: how long you've been trying, your age, your partner's fertility, and how your body responds.

For many women, the first step is lifestyle. Weight loss of even five to ten percent of body weight, where relevant, can meaningfully improve ovulation rates. Metformin, an insulin-sensitising medication originally used in type 2 diabetes, is often prescribed alongside lifestyle changes to improve insulin resistance and support cycle regularity.

If ovulation isn't occurring naturally, the next step is typically ovulation induction. Letrozole is now the preferred first-line agent in Australia. It works by temporarily lowering oestrogen levels, prompting the brain to release the hormones that drive follicle development. Clomiphene citrate is an older alternative still used in some cases. Both are taken orally for a short window early in the cycle, and response is monitored with ultrasound.

If oral ovulation induction doesn't work, injectable gonadotropins, hormones that directly stimulate the ovaries, may be used under closer monitoring given the higher risk of over-response. IVF becomes the pathway when other options have been exhausted, or when there are additional factors at play.

The medications involved and what to expect 

Fertility medications are time-sensitive in a way that most medications aren't. Letrozole is taken on specific days of your cycle, trigger injections are administered at a precise time before procedures, and progesterone support is often added in the second half of the cycle or after egg collection.

Getting this timing right matters. Missing a dose, taking something at the wrong point in the cycle, or having a medication that's been stored incorrectly can affect the outcome of a cycle. Fertility treatment is expensive and emotionally demanding, and the pharmacy handling your medication should understand that.

What your pharmacy needs to be doing

Some fertility medications require refrigeration. Progesterone pessaries, injectable gonadotropins, and certain trigger medications all have specific storage requirements, and some are not routinely stocked at community pharmacies. Specialty pharmacies with experience in fertility medication can ensure correct storage, have medications ready when you need them, and support the coordination that fertility cycles require.

Beyond logistics, your pharmacist should be someone you can contact with a question about your medication directly. That kind of accessibility matters more than usual when you're mid-cycle and trying to work out whether something you've noticed is normal.

How Ace supports PMOS patients

Ace works with fertility specialists and reproductive endocrinologists to support patients through every stage of PMOS management, from first prescription through to IVF. We can help ensure your medications are stored correctly, dispensed on time, and that you have someone to contact when questions come up.

Visit us at https://portal.acepharmacy.com.au or reach out through the portal directly.

This article is for general information only and does not constitute medical advice. PMOS affects every person differently, and treatment should always be guided by your specialist or GP based on your individual circumstances.